РИЧАРДСОН Питер (US),БОУМЕН Роберт А. (US),КОСТЕЛЛО Дональд (US)
申请号：
RU2012146344/15
公开号：
RU2012146344A
申请日:
2012.10.30
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating hyperglycemia and / or diabetes in a patient, comprising the step of administering to a patient in need of treatment a dry powder inhalation dosage form comprising a therapeutically effective amount of GLP-1, wherein said administration does not result in at least one side effect an effect selected from the group consisting of nausea, vomiting and increased sweating. 2. The method of claim 1, wherein the patient is a mammal suffering from type 2 diabetes. The method of claim 1, wherein the GLP-1 dosage form comprises from about 0.5 mg to about 3 mg of GLP-1.4. The method of claim 1, wherein the dry powder inhalation dosage form further comprises a DPP-IV.5 inhibitor. The method of claim 1, wherein the dry powder inhalation dosage form comprises diketopiperazine. The method of claim 5, wherein the diketopiperazine is 2,5-diketo-3,6-di (4-X-aminobutyl) piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl and fumaril, or a pharmaceutically acceptable thereof salt. 7. The method of claim 1, wherein GLP-1 is selected from the group consisting of native GLP-1, a metabolite of GLP-1, an analog of GLP-1, a derivative of GLP-1, an analogue of GLP-1 prolonged action, a GLP-1 mimetic, an exendin , a peptide analogue of GLP-1 or a biosynthetic analogue of GLP-1, or a combination thereof. 8. The method of claim 1, further comprising administering to the patient a therapeutically effective amount of insulin. The method of claim 8, wherein the dry powder inhalation dosage form comprises GLP-1 in combination with insulin. The method of claim 8, wherein the insulin is administered separately as a dry powder dosage form for inhalation. The method of claim 11. Способ лечения гипергликемии и/или диабета у пациента, включающий стадию введения прандиально пациенту, нуждающемуся в лечении, сухой порошковой лекарственной формы для ингаляции, включающей терапевтически эффективное количество GLP-1, где указанное введение не приводи
